Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 1999 February;134(1) > Giornale Italiano di Dermatologia e Venereologia 1999 February;134(1):61-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

THERAPEUTICAL NOTES   

Giornale Italiano di Dermatologia e Venereologia 1999 February;134(1):61-5

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: Italian

Efficacy and safety of the topical formulation of fluconazole 0.5% (gel containing an emulsion oil/water o/w) in the treatment of dermatomycoses with localized lesions: Results of a multicenter, open, non comparative study

Aste N. 1, Baldari U. 2, Bellini M. 3, Biggio P. 1, Pinna A. L. 1, Pau M. 1, Pavone P. S. 4, Righini M. G. 2, Vallecchi C. 3

1 Università degli Studi - Cagliari, Clinica Dermatologica; 2 Ospedale «G. B. Morgagni» - Forlì, Divisione di Dermatologia; 3 Università degli Studi - Firenze, Clinica Dermatologica; 4 Ospedale Generale di Zona - Menaggio (Como), Ambulatorio di Dermatologia


PDF


Efficacy and safety of the topical formulation of fluconazole 0.5% (gel containing an emulsion oil/water o/w) in the treatment of dermatomycoses with localized lesions: Results of a multicenter, open, non comparative study.
Background. Dermatophytoses are a group of diseases caused by keratinophilic mycetes involving the skin and its adnexa. At present, there is a wide range of antimycotic drugs which may be used by topical and systemic route with very good results and mild side-effects.
Methods. Seventy-one patients, 37 males and 34 females, age range 6-81 years, with Tinea corporis, Tinea cruris, Tinea pedis from dermatophytes or candida were treated with topical fluconazole 0.5%. The drug was applied once daily for an average period of 21±6 days.
Results. Fifty-seven patients completed the treatment and at the last follow-up 94% of them was completely cured and 6% improved. The therapeutic efficacy of topical fluconazole 0.5% resulted almost equivalent in the 3 groups: 96% of cure in patients with T. pedis, 93% in patients with T. corporis and 100% in those with T. cruris. The tolerability, both general and local, was good in 97.2% and 93% of cases, respectively. In only two cases mild and transient side effects occurred.
Conclusions. These results confirm that fluconazole, also in this new topical formulation 0.5%, is an innovative molecule, with a great antifungal potency and an excellent local tolerability.

top of page